A review of the history, properties, and use of the immunomodulatory compound lenalidomide

Annals of the New York Academy of Sciences

Volumn 1222, Issue 1, 2011, Pages 76-82

  Zeldis, Jerome B ^a   Knight, Robert ^a   Hussein, Mohamad ^a   Chopra, Rajesh ^a   Muller, George ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

IMiD; Immunomodulatory; Lenalidomide; Multiple myeloma; Myelodysplastic syndromes; REVLIMID

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOCETAXEL; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; THALIDOMIDE;

AMYLOIDOSIS; ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME 5Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GRAFT VERSUS HOST REACTION; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; POEMS SYNDROME; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEZARY CELL; SOLID TUMOR; STEM CELL TRANSPLANTATION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR FLARE; VENOUS THROMBOEMBOLISM;

EID: 79952842022     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05974.x     Document Type: Review

References (46)

1. Kurtin, S.E. & A.F. List 2009. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clin. Lymphoma. Myeloma. 9: E10-E13.
2. Kotla, V. 2009. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol. 2: 36.
3. Heise, C. 2010. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert. Rev. Anticancer. Ther. 10: 1663-1672.
4. Hideshima, T. 2000. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950.
5. Verhelle, D. 2007. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer. Res. 67: 746-755.
6. Gandhi, A.K. 2010. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr. Cancer. Drug. Targets. 10: 155-167.
7. Corral, L.G. 1999. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 163: 380-386.
8. Lopez-Girona, A. 2009. Lenalidomide inhibits the multiple myeloma cell survival factor IRF4/MUM1 [abstract]. Clin. Lymph. Myeloma. 9(Suppl 1): 309.
9. Mitsiades, N. 2002. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525-4530.
10. Ramsay, A.G. 2008. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118: 2427-2437.
11. Chang, D.H. 2006. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618-621.
12. Davies, F.E. 2001. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216.
13. Wu, L. 2008. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer. Res. 14: 4650-4657.
14. Galustian, C. 2009. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer. Immunol. Immunother. 58: 1033-1045.
15. Dredge, K. 2005. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc. Res. 69: 56-63.
16. Gupta, D. 2001. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic implications. Leukemia 15: 1950-1961.
17. Dimopoulos, M. 2007. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357: 2123-2132.
18. Weber, D.M. 2007. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357: 2133-2142.
19. Dimopoulos, M.A. 2009. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23: 2147-2152.
20. Rajkumar, S.V. 2005. Combination therapy with lenalidomide plus dexamethasone (rev/dex) for newly diagnosed myeloma. Blood 106: 4050-4053.
21. Rajkumar, S.V. 2010. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet. Oncol. 11: 29-37.
22. Palumbo, A. 2010. A phase 3 study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM) [abstract]. Haematologica 95(S2): 566.
23. McCarthy, P.L. 2010. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem hematopoietic cell transplant (AHSCT) for multiple myeloma (MM): CALGB 100104 [abstract]. Blood 116(Suppl): 37.
24. Attal, M. 2010. Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02 [abstract]. Blood 116(Suppl): 310.
25. List, A. 2005. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352: 549-557.
26. List, A. 2006. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355: 1456-1465.
27. Raza, A. 2008. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111: 86-93.
28. Chanan-Khan, A. 2006. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J. Clin. Oncol. 24: 5343-5349.
29. Ferrajoli, A. 2008. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111: 5291-5297.
30. Badoux, X. 2010. A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia [abstract]. J. Clin. Oncol. 28(Suppl): 6508.
31. Chen, C.I. 2009. Safety and efficacy of slow dose-escalation of lenalidomide for front-line treatment in chronic lymphocytic leukemia (CLL): results of a phase II study [abstract]. Haematologica. 94( S3 ): 10.29.
32. Sher, T. 2010. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk. Lymphoma. 51: 85-88.
33. Witzig, T.E. 2009. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J. Clin. Oncol. 27: 5404-5409.
34. Wiernik, P.H. 2008. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 26: 4952-4957.
35. Fowler, N.H. 2010. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma [abstract]. J. Clin. Oncol. 28(Suppl): 8036.
36. Habermann, T.M. 2009. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 145: 344-349.
37. Dueck, G. 2010. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116: 4541-4548.
38. Sanborn, S.L. 2009. Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest. New. Drugs. 27: 453-460.
39. Dahut, W.L. 2009. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J. Clin. Pharmacol. 49: 650-660.
40. Henry, J.Y. 2010. Effect of lenalidomide on the antiprostate cancer activity of docetaxel in vitro and in vivo [abstract]. J. Clin. Oncol. 28(Suppl): e13155.
41. Stadtmauer, E.A. 2007. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin. Adv. Hematol. Oncol. 5(10 Suppl 15): 7-19.
42. Palumbo, A. 2008. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414-423.
43. Ishak, J. 2008. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone [abstract]. Blood 112: 3708.
44. Miller, K.C. 2010. Management of patients with chronic lymphocytic leukemia treated with lenalidomide. Clin. J. Oncol. Nurs. 14: 491-499.
45. Palumbo, A. 2010. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J. Clin. Oncol. 28: 800-807.
46. Mateos, M.V. 2009. Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis [abstract]. Blood 114: 614.